nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—ABCC4—Sorafenib—thyroid cancer	0.284	1	CbGbCtD
Alprostadil—PTGER2—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.0176	0.0876	CbGpPWpGaD
Alprostadil—PTGER1—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.0119	0.0592	CbGpPWpGaD
Alprostadil—PTGIR—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.0119	0.0592	CbGpPWpGaD
Alprostadil—PTGER2—trachea—thyroid cancer	0.0114	0.107	CbGeAlD
Alprostadil—SLCO2A1—neck—thyroid cancer	0.00974	0.0909	CbGeAlD
Alprostadil—PTGER1—head—thyroid cancer	0.00762	0.0711	CbGeAlD
Alprostadil—SLCO2A1—saliva-secreting gland—thyroid cancer	0.0076	0.0709	CbGeAlD
Alprostadil—PTGER2—G alpha (s) signalling events—CALCB—thyroid cancer	0.007	0.0349	CbGpPWpGaD
Alprostadil—SLCO2A1—trachea—thyroid cancer	0.00586	0.0547	CbGeAlD
Alprostadil—PTGER2—lymph node—thyroid cancer	0.00563	0.0525	CbGeAlD
Alprostadil—SLCO2B1—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.00555	0.0277	CbGpPWpGaD
Alprostadil—PTGIR—thyroid gland—thyroid cancer	0.0053	0.0495	CbGeAlD
Alprostadil—PTGIR—G alpha (s) signalling events—CALCB—thyroid cancer	0.00473	0.0236	CbGpPWpGaD
Alprostadil—PTGIR—Endothelin Pathways—CALCA—thyroid cancer	0.00472	0.0236	CbGpPWpGaD
Alprostadil—PTGIR—head—thyroid cancer	0.00471	0.0439	CbGeAlD
Alprostadil—SLCO3A1—thyroid gland—thyroid cancer	0.00468	0.0437	CbGeAlD
Alprostadil—SLCO2A1—thyroid gland—thyroid cancer	0.00464	0.0433	CbGeAlD
Alprostadil—ABCC5—thyroid gland—thyroid cancer	0.00424	0.0396	CbGeAlD
Alprostadil—ABCC5—Defective B3GAT3 causes JDSSDHD—CHST14—thyroid cancer	0.0042	0.021	CbGpPWpGaD
Alprostadil—SLCO3A1—head—thyroid cancer	0.00415	0.0388	CbGeAlD
Alprostadil—SLCO2A1—head—thyroid cancer	0.00411	0.0384	CbGeAlD
Alprostadil—ABCC5—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.0038	0.019	CbGpPWpGaD
Alprostadil—Hypoglycaemia—Vandetanib—thyroid cancer	0.0035	0.00859	CcSEcCtD
Alprostadil—Lethargy—Vandetanib—thyroid cancer	0.00348	0.00855	CcSEcCtD
Alprostadil—Warmth—Doxorubicin—thyroid cancer	0.00341	0.00837	CcSEcCtD
Alprostadil—Anuria—Epirubicin—thyroid cancer	0.00335	0.00824	CcSEcCtD
Alprostadil—SLCO2B1—thyroid gland—thyroid cancer	0.00332	0.031	CbGeAlD
Alprostadil—PTGIR—lymph node—thyroid cancer	0.00329	0.0308	CbGeAlD
Alprostadil—Injection site inflammation—Doxorubicin—thyroid cancer	0.00325	0.00798	CcSEcCtD
Alprostadil—Cardiac arrest—Vandetanib—thyroid cancer	0.00324	0.00797	CcSEcCtD
Alprostadil—PTGER2—G alpha (s) signalling events—TSHR—thyroid cancer	0.00324	0.0162	CbGpPWpGaD
Alprostadil—Blood creatinine increased—Vandetanib—thyroid cancer	0.0032	0.00785	CcSEcCtD
Alprostadil—PTGER2—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.00315	0.0157	CbGpPWpGaD
Alprostadil—Supraventricular extrasystoles—Epirubicin—thyroid cancer	0.00315	0.00772	CcSEcCtD
Alprostadil—Hypokalaemia—Vandetanib—thyroid cancer	0.00311	0.00763	CcSEcCtD
Alprostadil—Anuria—Doxorubicin—thyroid cancer	0.0031	0.00762	CcSEcCtD
Alprostadil—Influenza like illness—Sorafenib—thyroid cancer	0.00308	0.00756	CcSEcCtD
Alprostadil—Hypochromic anaemia—Epirubicin—thyroid cancer	0.00302	0.00742	CcSEcCtD
Alprostadil—Influenza—Vandetanib—thyroid cancer	0.00295	0.00724	CcSEcCtD
Alprostadil—SLCO2B1—head—thyroid cancer	0.00294	0.0275	CbGeAlD
Alprostadil—ABCC4—thyroid gland—thyroid cancer	0.00294	0.0274	CbGeAlD
Alprostadil—Supraventricular extrasystoles—Doxorubicin—thyroid cancer	0.00291	0.00715	CcSEcCtD
Alprostadil—SLCO3A1—lymph node—thyroid cancer	0.00291	0.0271	CbGeAlD
Alprostadil—SLCO2A1—lymph node—thyroid cancer	0.00288	0.0269	CbGeAlD
Alprostadil—Bronchitis—Vandetanib—thyroid cancer	0.00284	0.00696	CcSEcCtD
Alprostadil—Tooth abscess—Epirubicin—thyroid cancer	0.00281	0.00689	CcSEcCtD
Alprostadil—Hypochromic anaemia—Doxorubicin—thyroid cancer	0.0028	0.00687	CcSEcCtD
Alprostadil—Prostatic disorder—Epirubicin—thyroid cancer	0.00276	0.00677	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Vandetanib—thyroid cancer	0.00274	0.00673	CcSEcCtD
Alprostadil—Pollakiuria—Vandetanib—thyroid cancer	0.00272	0.00669	CcSEcCtD
Alprostadil—Hyperglycaemia—Vandetanib—thyroid cancer	0.00266	0.00653	CcSEcCtD
Alprostadil—ABCC5—lymph node—thyroid cancer	0.00263	0.0246	CbGeAlD
Alprostadil—ABCC4—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.00263	0.0131	CbGpPWpGaD
Alprostadil—ABCC4—head—thyroid cancer	0.00261	0.0243	CbGeAlD
Alprostadil—Tooth abscess—Doxorubicin—thyroid cancer	0.0026	0.00637	CcSEcCtD
Alprostadil—Renal failure—Vandetanib—thyroid cancer	0.00258	0.00635	CcSEcCtD
Alprostadil—Urinary tract infection—Vandetanib—thyroid cancer	0.00256	0.00628	CcSEcCtD
Alprostadil—Prostatic disorder—Doxorubicin—thyroid cancer	0.00255	0.00626	CcSEcCtD
Alprostadil—PTGER2—GPCR ligand binding—CALCB—thyroid cancer	0.00254	0.0127	CbGpPWpGaD
Alprostadil—Cardiac failure congestive—Sorafenib—thyroid cancer	0.00254	0.00623	CcSEcCtD
Alprostadil—Haematuria—Vandetanib—thyroid cancer	0.00251	0.00616	CcSEcCtD
Alprostadil—Sinusitis—Vandetanib—thyroid cancer	0.00247	0.00606	CcSEcCtD
Alprostadil—ABCC4—Ectoderm Differentiation—TRIM33—thyroid cancer	0.00245	0.0122	CbGpPWpGaD
Alprostadil—PTGER2—G alpha (s) signalling events—CALCA—thyroid cancer	0.00242	0.0121	CbGpPWpGaD
Alprostadil—Bradycardia—Vandetanib—thyroid cancer	0.0024	0.0059	CcSEcCtD
Alprostadil—Peripheral vascular disorder—Epirubicin—thyroid cancer	0.00239	0.00587	CcSEcCtD
Alprostadil—Haemoglobin—Vandetanib—thyroid cancer	0.00237	0.00583	CcSEcCtD
Alprostadil—Haemorrhage—Vandetanib—thyroid cancer	0.00236	0.0058	CcSEcCtD
Alprostadil—Pneumothorax—Epirubicin—thyroid cancer	0.00236	0.00578	CcSEcCtD
Alprostadil—Urethral disorder—Vandetanib—thyroid cancer	0.00231	0.00568	CcSEcCtD
Alprostadil—Pain in extremity—Sorafenib—thyroid cancer	0.0023	0.00565	CcSEcCtD
Alprostadil—Visual impairment—Vandetanib—thyroid cancer	0.00227	0.00559	CcSEcCtD
Alprostadil—ABCC5—Carbohydrate metabolism—CHST14—thyroid cancer	0.00225	0.0112	CbGpPWpGaD
Alprostadil—Peripheral vascular disorder—Doxorubicin—thyroid cancer	0.00221	0.00543	CcSEcCtD
Alprostadil—PTGIR—G alpha (s) signalling events—TSHR—thyroid cancer	0.00219	0.0109	CbGpPWpGaD
Alprostadil—Pneumothorax—Doxorubicin—thyroid cancer	0.00218	0.00535	CcSEcCtD
Alprostadil—PTGER1—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.00213	0.0106	CbGpPWpGaD
Alprostadil—PTGIR—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.00213	0.0106	CbGpPWpGaD
Alprostadil—Local reaction—Epirubicin—thyroid cancer	0.00212	0.0052	CcSEcCtD
Alprostadil—Hypokalaemia—Sorafenib—thyroid cancer	0.00209	0.00514	CcSEcCtD
Alprostadil—Hypothermia—Epirubicin—thyroid cancer	0.00209	0.00513	CcSEcCtD
Alprostadil—Body temperature decreased—Epirubicin—thyroid cancer	0.00209	0.00513	CcSEcCtD
Alprostadil—SLCO2B1—lymph node—thyroid cancer	0.00206	0.0192	CbGeAlD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.00198	0.00988	CbGpPWpGaD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—CP—thyroid cancer	0.00198	0.00988	CbGpPWpGaD
Alprostadil—Muscle spasms—Vandetanib—thyroid cancer	0.00198	0.00485	CcSEcCtD
Alprostadil—Local reaction—Doxorubicin—thyroid cancer	0.00196	0.00481	CcSEcCtD
Alprostadil—Hypothermia—Doxorubicin—thyroid cancer	0.00193	0.00475	CcSEcCtD
Alprostadil—Body temperature decreased—Doxorubicin—thyroid cancer	0.00193	0.00475	CcSEcCtD
Alprostadil—Pelvic pain—Epirubicin—thyroid cancer	0.00193	0.00473	CcSEcCtD
Alprostadil—Serum creatinine increased—Epirubicin—thyroid cancer	0.00191	0.00468	CcSEcCtD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.00188	0.00937	CbGpPWpGaD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—CP—thyroid cancer	0.00188	0.00937	CbGpPWpGaD
Alprostadil—ABCC4—lymph node—thyroid cancer	0.00183	0.017	CbGeAlD
Alprostadil—Loss of consciousness—Vandetanib—thyroid cancer	0.00181	0.00443	CcSEcCtD
Alprostadil—Cough—Vandetanib—thyroid cancer	0.00179	0.0044	CcSEcCtD
Alprostadil—Pelvic pain—Doxorubicin—thyroid cancer	0.00178	0.00438	CcSEcCtD
Alprostadil—Convulsion—Vandetanib—thyroid cancer	0.00178	0.00437	CcSEcCtD
Alprostadil—Hypertension—Vandetanib—thyroid cancer	0.00177	0.00436	CcSEcCtD
Alprostadil—Dihomo-gamma-linolenic acid—PTGS2—thyroid cancer	0.00177	1	CrCbGaD
Alprostadil—Serum creatinine increased—Doxorubicin—thyroid cancer	0.00176	0.00433	CcSEcCtD
Alprostadil—Acute coronary syndrome—Sorafenib—thyroid cancer	0.00175	0.00429	CcSEcCtD
Alprostadil—Renal failure—Sorafenib—thyroid cancer	0.00174	0.00428	CcSEcCtD
Alprostadil—Myocardial infarction—Sorafenib—thyroid cancer	0.00174	0.00427	CcSEcCtD
Alprostadil—Redness—Epirubicin—thyroid cancer	0.00174	0.00426	CcSEcCtD
Alprostadil—PTGIR—GPCR ligand binding—CALCB—thyroid cancer	0.00172	0.00856	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—CALCB—thyroid cancer	0.00172	0.00856	CbGpPWpGaD
Alprostadil—Dry mouth—Vandetanib—thyroid cancer	0.00171	0.0042	CcSEcCtD
Alprostadil—Burning sensation—Epirubicin—thyroid cancer	0.00169	0.00414	CcSEcCtD
Alprostadil—Oedema—Vandetanib—thyroid cancer	0.00168	0.00412	CcSEcCtD
Alprostadil—Infection—Vandetanib—thyroid cancer	0.00167	0.00409	CcSEcCtD
Alprostadil—Thrombocytopenia—Vandetanib—thyroid cancer	0.00164	0.00403	CcSEcCtD
Alprostadil—PTGIR—G alpha (s) signalling events—CALCA—thyroid cancer	0.00164	0.00817	CbGpPWpGaD
Alprostadil—ABCC4—Ectoderm Differentiation—TCF7L1—thyroid cancer	0.00164	0.00816	CbGpPWpGaD
Alprostadil—Skin disorder—Vandetanib—thyroid cancer	0.00163	0.004	CcSEcCtD
Alprostadil—Redness—Doxorubicin—thyroid cancer	0.00161	0.00394	CcSEcCtD
Alprostadil—Haemoglobin—Sorafenib—thyroid cancer	0.0016	0.00393	CcSEcCtD
Alprostadil—Haemorrhage—Sorafenib—thyroid cancer	0.00159	0.00391	CcSEcCtD
Alprostadil—Urethral disorder—Sorafenib—thyroid cancer	0.00156	0.00383	CcSEcCtD
Alprostadil—Burning sensation—Doxorubicin—thyroid cancer	0.00156	0.00383	CcSEcCtD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00154	0.00771	CbGpPWpGaD
Alprostadil—Fungal infection—Epirubicin—thyroid cancer	0.00152	0.00373	CcSEcCtD
Alprostadil—Feeling hot—Epirubicin—thyroid cancer	0.00149	0.00367	CcSEcCtD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.00148	0.0074	CbGpPWpGaD
Alprostadil—Flushing—Sorafenib—thyroid cancer	0.00148	0.00363	CcSEcCtD
Alprostadil—Dyspepsia—Vandetanib—thyroid cancer	0.00148	0.00362	CcSEcCtD
Alprostadil—PTGER2—GPCR downstream signaling—CALCB—thyroid cancer	0.00144	0.00716	CbGpPWpGaD
Alprostadil—Injection site pain—Epirubicin—thyroid cancer	0.00144	0.00352	CcSEcCtD
Alprostadil—Pain—Vandetanib—thyroid cancer	0.00143	0.00352	CcSEcCtD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.00141	0.00701	CbGpPWpGaD
Alprostadil—Fungal infection—Doxorubicin—thyroid cancer	0.0014	0.00345	CcSEcCtD
Alprostadil—Erythema—Sorafenib—thyroid cancer	0.00139	0.0034	CcSEcCtD
Alprostadil—Feeling hot—Doxorubicin—thyroid cancer	0.00138	0.00339	CcSEcCtD
Alprostadil—Vasodilation—Epirubicin—thyroid cancer	0.00133	0.00327	CcSEcCtD
Alprostadil—Vasodilation procedure—Epirubicin—thyroid cancer	0.00133	0.00327	CcSEcCtD
Alprostadil—Muscle spasms—Sorafenib—thyroid cancer	0.00133	0.00327	CcSEcCtD
Alprostadil—Injection site pain—Doxorubicin—thyroid cancer	0.00133	0.00326	CcSEcCtD
Alprostadil—Body temperature increased—Vandetanib—thyroid cancer	0.00133	0.00326	CcSEcCtD
Alprostadil—Abdominal pain—Vandetanib—thyroid cancer	0.00133	0.00326	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—CALCB—thyroid cancer	0.0013	0.0065	CbGpPWpGaD
Alprostadil—Hyperbilirubinaemia—Epirubicin—thyroid cancer	0.00129	0.00316	CcSEcCtD
Alprostadil—Anaemia—Sorafenib—thyroid cancer	0.00128	0.00315	CcSEcCtD
Alprostadil—Syncope—Sorafenib—thyroid cancer	0.00124	0.00305	CcSEcCtD
Alprostadil—ABCC5—NRF2 pathway—SLC5A5—thyroid cancer	0.00124	0.00617	CbGpPWpGaD
Alprostadil—Vasodilation—Doxorubicin—thyroid cancer	0.00123	0.00303	CcSEcCtD
Alprostadil—Vasodilation procedure—Doxorubicin—thyroid cancer	0.00123	0.00303	CcSEcCtD
Alprostadil—Loss of consciousness—Sorafenib—thyroid cancer	0.00122	0.00299	CcSEcCtD
Alprostadil—Cough—Sorafenib—thyroid cancer	0.00121	0.00297	CcSEcCtD
Alprostadil—Asthenia—Vandetanib—thyroid cancer	0.0012	0.00295	CcSEcCtD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.0012	0.00599	CbGpPWpGaD
Alprostadil—Hypertension—Sorafenib—thyroid cancer	0.0012	0.00294	CcSEcCtD
Alprostadil—Hyperbilirubinaemia—Doxorubicin—thyroid cancer	0.00119	0.00293	CcSEcCtD
Alprostadil—Pruritus—Vandetanib—thyroid cancer	0.00119	0.00291	CcSEcCtD
Alprostadil—PTGER2—GPCR ligand binding—TSHR—thyroid cancer	0.00118	0.00587	CbGpPWpGaD
Alprostadil—Injection site reaction—Epirubicin—thyroid cancer	0.00116	0.00286	CcSEcCtD
Alprostadil—Dry mouth—Sorafenib—thyroid cancer	0.00115	0.00283	CcSEcCtD
Alprostadil—Hyperkalaemia—Epirubicin—thyroid cancer	0.00115	0.00283	CcSEcCtD
Alprostadil—Diarrhoea—Vandetanib—thyroid cancer	0.00115	0.00282	CcSEcCtD
Alprostadil—Influenza like illness—Epirubicin—thyroid cancer	0.00114	0.00279	CcSEcCtD
Alprostadil—Infection—Sorafenib—thyroid cancer	0.00112	0.00276	CcSEcCtD
Alprostadil—Shock—Sorafenib—thyroid cancer	0.00111	0.00273	CcSEcCtD
Alprostadil—Dizziness—Vandetanib—thyroid cancer	0.00111	0.00272	CcSEcCtD
Alprostadil—Thrombocytopenia—Sorafenib—thyroid cancer	0.00111	0.00272	CcSEcCtD
Alprostadil—Skin disorder—Sorafenib—thyroid cancer	0.0011	0.0027	CcSEcCtD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—CP—thyroid cancer	0.00109	0.00543	CbGpPWpGaD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.00109	0.00543	CbGpPWpGaD
Alprostadil—Injection site reaction—Doxorubicin—thyroid cancer	0.00108	0.00265	CcSEcCtD
Alprostadil—Cramps of lower extremities—Epirubicin—thyroid cancer	0.00108	0.00264	CcSEcCtD
Alprostadil—Hyperkalaemia—Doxorubicin—thyroid cancer	0.00107	0.00262	CcSEcCtD
Alprostadil—Ecchymosis—Epirubicin—thyroid cancer	0.00106	0.0026	CcSEcCtD
Alprostadil—Rash—Vandetanib—thyroid cancer	0.00106	0.0026	CcSEcCtD
Alprostadil—Dermatitis—Vandetanib—thyroid cancer	0.00106	0.00259	CcSEcCtD
Alprostadil—Influenza like illness—Doxorubicin—thyroid cancer	0.00105	0.00259	CcSEcCtD
Alprostadil—Headache—Vandetanib—thyroid cancer	0.00105	0.00258	CcSEcCtD
Alprostadil—ABCC5—Carbohydrate metabolism—TPR—thyroid cancer	0.00104	0.00521	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00104	0.00521	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00104	0.00521	CbGpPWpGaD
Alprostadil—ABCC5—NRF2 pathway—RXRA—thyroid cancer	0.00104	0.00518	CbGpPWpGaD
Alprostadil—Abnormal vision—Epirubicin—thyroid cancer	0.00102	0.00251	CcSEcCtD
Alprostadil—Sepsis—Epirubicin—thyroid cancer	0.00102	0.0025	CcSEcCtD
Alprostadil—ABCC5—Fluoropyrimidine Activity—TP53—thyroid cancer	0.00101	0.00503	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.00101	0.00502	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—CP—thyroid cancer	0.00101	0.00502	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—PTCH1—thyroid cancer	0.001	0.00499	CbGpPWpGaD
Alprostadil—Nausea—Vandetanib—thyroid cancer	0.000996	0.00245	CcSEcCtD
Alprostadil—Cramps of lower extremities—Doxorubicin—thyroid cancer	0.000996	0.00245	CcSEcCtD
Alprostadil—Dyspepsia—Sorafenib—thyroid cancer	0.000996	0.00245	CcSEcCtD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.00099	0.00494	CbGpPWpGaD
Alprostadil—Ecchymosis—Doxorubicin—thyroid cancer	0.00098	0.00241	CcSEcCtD
Alprostadil—Diabetes mellitus—Epirubicin—thyroid cancer	0.000978	0.0024	CcSEcCtD
Alprostadil—PTGER1—GPCR downstream signaling—CALCB—thyroid cancer	0.00097	0.00484	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—CALCB—thyroid cancer	0.00097	0.00484	CbGpPWpGaD
Alprostadil—Pain—Sorafenib—thyroid cancer	0.000967	0.00238	CcSEcCtD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.000955	0.00476	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000954	0.00476	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000954	0.00476	CbGpPWpGaD
Alprostadil—Abnormal vision—Doxorubicin—thyroid cancer	0.000946	0.00232	CcSEcCtD
Alprostadil—Sepsis—Doxorubicin—thyroid cancer	0.000941	0.00231	CcSEcCtD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000939	0.00468	CbGpPWpGaD
Alprostadil—Cardiac failure congestive—Epirubicin—thyroid cancer	0.000938	0.0023	CcSEcCtD
Alprostadil—PTGER2—GPCR ligand binding—SST—thyroid cancer	0.000915	0.00456	CbGpPWpGaD
Alprostadil—Diabetes mellitus—Doxorubicin—thyroid cancer	0.000905	0.00222	CcSEcCtD
Alprostadil—ABCC5—NRF2 pathway—NRG1—thyroid cancer	0.000898	0.00448	CbGpPWpGaD
Alprostadil—Body temperature increased—Sorafenib—thyroid cancer	0.000894	0.0022	CcSEcCtD
Alprostadil—Abdominal pain—Sorafenib—thyroid cancer	0.000894	0.0022	CcSEcCtD
Alprostadil—PTGIR—Signaling by GPCR—CALCB—thyroid cancer	0.000881	0.00439	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CALCB—thyroid cancer	0.000881	0.00439	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—CALCA—thyroid cancer	0.00088	0.00439	CbGpPWpGaD
Alprostadil—Hypoglycaemia—Epirubicin—thyroid cancer	0.000872	0.00214	CcSEcCtD
Alprostadil—Lethargy—Epirubicin—thyroid cancer	0.000868	0.00213	CcSEcCtD
Alprostadil—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.000868	0.00213	CcSEcCtD
Alprostadil—ABCC4—NRF2 pathway—SLC5A5—thyroid cancer	0.000857	0.00427	CbGpPWpGaD
Alprostadil—Pain in extremity—Epirubicin—thyroid cancer	0.000851	0.00209	CcSEcCtD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000815	0.00407	CbGpPWpGaD
Alprostadil—Asthenia—Sorafenib—thyroid cancer	0.000812	0.00199	CcSEcCtD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000811	0.00405	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000811	0.00405	CbGpPWpGaD
Alprostadil—Cardiac arrest—Epirubicin—thyroid cancer	0.000809	0.00199	CcSEcCtD
Alprostadil—Hypoglycaemia—Doxorubicin—thyroid cancer	0.000806	0.00198	CcSEcCtD
Alprostadil—Lethargy—Doxorubicin—thyroid cancer	0.000803	0.00197	CcSEcCtD
Alprostadil—Pruritus—Sorafenib—thyroid cancer	0.0008	0.00197	CcSEcCtD
Alprostadil—Blood creatinine increased—Epirubicin—thyroid cancer	0.000797	0.00196	CcSEcCtD
Alprostadil—PTGIR—GPCR ligand binding—TSHR—thyroid cancer	0.000794	0.00396	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—TSHR—thyroid cancer	0.000794	0.00396	CbGpPWpGaD
Alprostadil—Pain in extremity—Doxorubicin—thyroid cancer	0.000787	0.00193	CcSEcCtD
Alprostadil—Hypokalaemia—Epirubicin—thyroid cancer	0.000774	0.0019	CcSEcCtD
Alprostadil—Diarrhoea—Sorafenib—thyroid cancer	0.000774	0.0019	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—CALCB—thyroid cancer	0.00077	0.00384	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000754	0.00376	CbGpPWpGaD
Alprostadil—Cardiac arrest—Doxorubicin—thyroid cancer	0.000748	0.00184	CcSEcCtD
Alprostadil—Dizziness—Sorafenib—thyroid cancer	0.000748	0.00184	CcSEcCtD
Alprostadil—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000737	0.00181	CcSEcCtD
Alprostadil—Influenza—Epirubicin—thyroid cancer	0.000735	0.00181	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—TRIM33—thyroid cancer	0.00073	0.00364	CbGpPWpGaD
Alprostadil—ABCC4—NRF2 pathway—RXRA—thyroid cancer	0.00072	0.00359	CbGpPWpGaD
Alprostadil—Hypokalaemia—Doxorubicin—thyroid cancer	0.000716	0.00176	CcSEcCtD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000714	0.00356	CbGpPWpGaD
Alprostadil—Rash—Sorafenib—thyroid cancer	0.000713	0.00175	CcSEcCtD
Alprostadil—Dermatitis—Sorafenib—thyroid cancer	0.000713	0.00175	CcSEcCtD
Alprostadil—Headache—Sorafenib—thyroid cancer	0.000709	0.00174	CcSEcCtD
Alprostadil—Bronchitis—Epirubicin—thyroid cancer	0.000707	0.00174	CcSEcCtD
Alprostadil—ABCC4—Fluoropyrimidine Activity—TP53—thyroid cancer	0.000699	0.00349	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—PRKAR1A—thyroid cancer	0.000699	0.00349	CbGpPWpGaD
Alprostadil—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000683	0.00168	CcSEcCtD
Alprostadil—Influenza—Doxorubicin—thyroid cancer	0.00068	0.00167	CcSEcCtD
Alprostadil—ABCC5—Disease—TRIM24—thyroid cancer	0.000679	0.00339	CbGpPWpGaD
Alprostadil—Pollakiuria—Epirubicin—thyroid cancer	0.000679	0.00167	CcSEcCtD
Alprostadil—PTGIR—GPCR ligand binding—PTCH1—thyroid cancer	0.000675	0.00337	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—PTCH1—thyroid cancer	0.000675	0.00337	CbGpPWpGaD
Alprostadil—Nausea—Sorafenib—thyroid cancer	0.000672	0.00165	CcSEcCtD
Alprostadil—ABCC5—Metabolism—MINPP1—thyroid cancer	0.000669	0.00334	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—TSHR—thyroid cancer	0.000665	0.00332	CbGpPWpGaD
Alprostadil—Hyperglycaemia—Epirubicin—thyroid cancer	0.000663	0.00163	CcSEcCtD
Alprostadil—Bronchitis—Doxorubicin—thyroid cancer	0.000654	0.00161	CcSEcCtD
Alprostadil—PTGIR—Thromboxane A2 receptor signaling—AKT1—thyroid cancer	0.000649	0.00324	CbGpPWpGaD
Alprostadil—Renal failure—Epirubicin—thyroid cancer	0.000644	0.00158	CcSEcCtD
Alprostadil—ABCC5—Disease—CHST14—thyroid cancer	0.000639	0.00319	CbGpPWpGaD
Alprostadil—Urinary tract infection—Epirubicin—thyroid cancer	0.000637	0.00156	CcSEcCtD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000633	0.00316	CbGpPWpGaD
Alprostadil—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000632	0.00155	CcSEcCtD
Alprostadil—Pollakiuria—Doxorubicin—thyroid cancer	0.000628	0.00154	CcSEcCtD
Alprostadil—Haematuria—Epirubicin—thyroid cancer	0.000625	0.00153	CcSEcCtD
Alprostadil—ABCC4—NRF2 pathway—NRG1—thyroid cancer	0.000622	0.00311	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—SST—thyroid cancer	0.000618	0.00308	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—SST—thyroid cancer	0.000618	0.00308	CbGpPWpGaD
Alprostadil—Sinusitis—Epirubicin—thyroid cancer	0.000615	0.00151	CcSEcCtD
Alprostadil—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000614	0.00151	CcSEcCtD
Alprostadil—ABCC5—Disease—TRIM33—thyroid cancer	0.000606	0.00302	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—TSHR—thyroid cancer	0.000604	0.00301	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.0006	0.00299	CbGpPWpGaD
Alprostadil—Bradycardia—Epirubicin—thyroid cancer	0.000599	0.00147	CcSEcCtD
Alprostadil—Renal failure—Doxorubicin—thyroid cancer	0.000596	0.00146	CcSEcCtD
Alprostadil—PTGIR—GPCR ligand binding—CALCA—thyroid cancer	0.000595	0.00297	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—CALCA—thyroid cancer	0.000595	0.00297	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000594	0.00296	CbGpPWpGaD
Alprostadil—Haemoglobin—Epirubicin—thyroid cancer	0.000591	0.00145	CcSEcCtD
Alprostadil—Rhinitis—Epirubicin—thyroid cancer	0.00059	0.00145	CcSEcCtD
Alprostadil—Urinary tract infection—Doxorubicin—thyroid cancer	0.00059	0.00145	CcSEcCtD
Alprostadil—Haemorrhage—Epirubicin—thyroid cancer	0.000588	0.00144	CcSEcCtD
Alprostadil—Hypoaesthesia—Epirubicin—thyroid cancer	0.000586	0.00144	CcSEcCtD
Alprostadil—Pharyngitis—Epirubicin—thyroid cancer	0.000584	0.00143	CcSEcCtD
Alprostadil—Haematuria—Doxorubicin—thyroid cancer	0.000578	0.00142	CcSEcCtD
Alprostadil—Urethral disorder—Epirubicin—thyroid cancer	0.000577	0.00142	CcSEcCtD
Alprostadil—Sinusitis—Doxorubicin—thyroid cancer	0.000569	0.0014	CcSEcCtD
Alprostadil—ABCC5—Metabolism—NDUFA13—thyroid cancer	0.000569	0.00284	CbGpPWpGaD
Alprostadil—Visual impairment—Epirubicin—thyroid cancer	0.000567	0.00139	CcSEcCtD
Alprostadil—Bradycardia—Doxorubicin—thyroid cancer	0.000554	0.00136	CcSEcCtD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000553	0.00276	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000553	0.00276	CbGpPWpGaD
Alprostadil—Haemoglobin—Doxorubicin—thyroid cancer	0.000547	0.00134	CcSEcCtD
Alprostadil—Flushing—Epirubicin—thyroid cancer	0.000546	0.00134	CcSEcCtD
Alprostadil—Rhinitis—Doxorubicin—thyroid cancer	0.000546	0.00134	CcSEcCtD
Alprostadil—Haemorrhage—Doxorubicin—thyroid cancer	0.000544	0.00134	CcSEcCtD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000544	0.00272	CbGpPWpGaD
Alprostadil—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000542	0.00133	CcSEcCtD
Alprostadil—Pharyngitis—Doxorubicin—thyroid cancer	0.00054	0.00133	CcSEcCtD
Alprostadil—ABCC5—Metabolism—CHST14—thyroid cancer	0.000535	0.00267	CbGpPWpGaD
Alprostadil—Urethral disorder—Doxorubicin—thyroid cancer	0.000534	0.00131	CcSEcCtD
Alprostadil—ABCC5—Transmembrane transport of small molecules—CP—thyroid cancer	0.000529	0.00264	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000529	0.00264	CbGpPWpGaD
Alprostadil—Visual impairment—Doxorubicin—thyroid cancer	0.000525	0.00129	CcSEcCtD
Alprostadil—ABCC5—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.00052	0.0026	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CALCB—thyroid cancer	0.00052	0.0026	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CALCB—thyroid cancer	0.00052	0.0026	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—SST—thyroid cancer	0.000517	0.00258	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PTCH1—thyroid cancer	0.000513	0.00256	CbGpPWpGaD
Alprostadil—Erythema—Epirubicin—thyroid cancer	0.000512	0.00126	CcSEcCtD
Alprostadil—Flushing—Doxorubicin—thyroid cancer	0.000505	0.00124	CcSEcCtD
Alprostadil—Nervousness—Epirubicin—thyroid cancer	0.000498	0.00122	CcSEcCtD
Alprostadil—PTGER2—GPCR downstream signaling—CALCA—thyroid cancer	0.000498	0.00248	CbGpPWpGaD
Alprostadil—Back pain—Epirubicin—thyroid cancer	0.000496	0.00122	CcSEcCtD
Alprostadil—PTGER1—Signaling Pathways—TRIM33—thyroid cancer	0.000493	0.00246	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TRIM33—thyroid cancer	0.000493	0.00246	CbGpPWpGaD
Alprostadil—Muscle spasms—Epirubicin—thyroid cancer	0.000493	0.00121	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—TCF7L1—thyroid cancer	0.000487	0.00243	CbGpPWpGaD
Alprostadil—Erythema—Doxorubicin—thyroid cancer	0.000474	0.00116	CcSEcCtD
Alprostadil—Anaemia—Epirubicin—thyroid cancer	0.000473	0.00116	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—SST—thyroid cancer	0.000469	0.00234	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—IFNA2—thyroid cancer	0.000463	0.00231	CbGpPWpGaD
Alprostadil—Nervousness—Doxorubicin—thyroid cancer	0.00046	0.00113	CcSEcCtD
Alprostadil—Syncope—Epirubicin—thyroid cancer	0.000459	0.00113	CcSEcCtD
Alprostadil—Back pain—Doxorubicin—thyroid cancer	0.000458	0.00113	CcSEcCtD
Alprostadil—Muscle spasms—Doxorubicin—thyroid cancer	0.000456	0.00112	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—CALCA—thyroid cancer	0.000452	0.00225	CbGpPWpGaD
Alprostadil—Loss of consciousness—Epirubicin—thyroid cancer	0.00045	0.00111	CcSEcCtD
Alprostadil—PTGIR—GPCR downstream signaling—TSHR—thyroid cancer	0.000449	0.00224	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—TSHR—thyroid cancer	0.000449	0.00224	CbGpPWpGaD
Alprostadil—Cough—Epirubicin—thyroid cancer	0.000447	0.0011	CcSEcCtD
Alprostadil—Convulsion—Epirubicin—thyroid cancer	0.000444	0.00109	CcSEcCtD
Alprostadil—Hypertension—Epirubicin—thyroid cancer	0.000442	0.00109	CcSEcCtD
Alprostadil—Anaemia—Doxorubicin—thyroid cancer	0.000438	0.00108	CcSEcCtD
Alprostadil—ABCC5—Metabolism—HPGD—thyroid cancer	0.000431	0.00215	CbGpPWpGaD
Alprostadil—Discomfort—Epirubicin—thyroid cancer	0.000431	0.00106	CcSEcCtD
Alprostadil—Dry mouth—Epirubicin—thyroid cancer	0.000427	0.00105	CcSEcCtD
Alprostadil—Syncope—Doxorubicin—thyroid cancer	0.000425	0.00104	CcSEcCtD
Alprostadil—Oedema—Epirubicin—thyroid cancer	0.000418	0.00103	CcSEcCtD
Alprostadil—Loss of consciousness—Doxorubicin—thyroid cancer	0.000417	0.00102	CcSEcCtD
Alprostadil—ABCC4—Hemostasis—PRKAR1A—thyroid cancer	0.000417	0.00208	CbGpPWpGaD
Alprostadil—Infection—Epirubicin—thyroid cancer	0.000415	0.00102	CcSEcCtD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000414	0.00207	CbGpPWpGaD
Alprostadil—Cough—Doxorubicin—thyroid cancer	0.000414	0.00102	CcSEcCtD
Alprostadil—Shock—Epirubicin—thyroid cancer	0.000411	0.00101	CcSEcCtD
Alprostadil—Convulsion—Doxorubicin—thyroid cancer	0.000411	0.00101	CcSEcCtD
Alprostadil—Thrombocytopenia—Epirubicin—thyroid cancer	0.000409	0.00101	CcSEcCtD
Alprostadil—Hypertension—Doxorubicin—thyroid cancer	0.000409	0.001	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—CDK1—thyroid cancer	0.000409	0.00204	CbGpPWpGaD
Alprostadil—Tachycardia—Epirubicin—thyroid cancer	0.000408	0.001	CcSEcCtD
Alprostadil—PTGER1—Signaling by GPCR—TSHR—thyroid cancer	0.000408	0.00203	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—TSHR—thyroid cancer	0.000408	0.00203	CbGpPWpGaD
Alprostadil—Skin disorder—Epirubicin—thyroid cancer	0.000406	0.000997	CcSEcCtD
Alprostadil—Hyperhidrosis—Epirubicin—thyroid cancer	0.000404	0.000992	CcSEcCtD
Alprostadil—ABCC5—Disease—TCF7L1—thyroid cancer	0.000404	0.00202	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000401	0.002	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000401	0.002	CbGpPWpGaD
Alprostadil—Discomfort—Doxorubicin—thyroid cancer	0.000399	0.000979	CcSEcCtD
Alprostadil—ABCC5—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000396	0.00198	CbGpPWpGaD
Alprostadil—Dry mouth—Doxorubicin—thyroid cancer	0.000395	0.000969	CcSEcCtD
Alprostadil—Hypotension—Epirubicin—thyroid cancer	0.000391	0.000959	CcSEcCtD
Alprostadil—Oedema—Doxorubicin—thyroid cancer	0.000387	0.00095	CcSEcCtD
Alprostadil—Infection—Doxorubicin—thyroid cancer	0.000384	0.000944	CcSEcCtD
Alprostadil—Shock—Doxorubicin—thyroid cancer	0.000381	0.000935	CcSEcCtD
Alprostadil—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000379	0.00093	CcSEcCtD
Alprostadil—Tachycardia—Doxorubicin—thyroid cancer	0.000378	0.000927	CcSEcCtD
Alprostadil—Skin disorder—Doxorubicin—thyroid cancer	0.000376	0.000923	CcSEcCtD
Alprostadil—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000374	0.000918	CcSEcCtD
Alprostadil—Dyspepsia—Epirubicin—thyroid cancer	0.000368	0.000904	CcSEcCtD
Alprostadil—ABCC4—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000367	0.00183	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—CP—thyroid cancer	0.000367	0.00183	CbGpPWpGaD
Alprostadil—Hypotension—Doxorubicin—thyroid cancer	0.000361	0.000888	CcSEcCtD
Alprostadil—ABCC4—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000361	0.0018	CbGpPWpGaD
Alprostadil—Pain—Epirubicin—thyroid cancer	0.000358	0.000878	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—TSHR—thyroid cancer	0.000357	0.00178	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PRKAR1A—thyroid cancer	0.000351	0.00175	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—SST—thyroid cancer	0.000349	0.00174	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—SST—thyroid cancer	0.000349	0.00174	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000348	0.00174	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PTCH1—thyroid cancer	0.000347	0.00173	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PTCH1—thyroid cancer	0.000347	0.00173	CbGpPWpGaD
Alprostadil—Feeling abnormal—Epirubicin—thyroid cancer	0.000345	0.000846	CcSEcCtD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000342	0.00171	CbGpPWpGaD
Alprostadil—Dyspepsia—Doxorubicin—thyroid cancer	0.000341	0.000836	CcSEcCtD
Alprostadil—PTGIR—GPCR downstream signaling—CALCA—thyroid cancer	0.000336	0.00168	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—CALCA—thyroid cancer	0.000336	0.00168	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MEN1—thyroid cancer	0.000335	0.00167	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000333	0.00166	CbGpPWpGaD
Alprostadil—Pain—Doxorubicin—thyroid cancer	0.000331	0.000812	CcSEcCtD
Alprostadil—Abdominal pain—Epirubicin—thyroid cancer	0.00033	0.000812	CcSEcCtD
Alprostadil—Body temperature increased—Epirubicin—thyroid cancer	0.00033	0.000812	CcSEcCtD
Alprostadil—PTGER1—Signaling Pathways—TCF7L1—thyroid cancer	0.000329	0.00164	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TCF7L1—thyroid cancer	0.000329	0.00164	CbGpPWpGaD
Alprostadil—Feeling abnormal—Doxorubicin—thyroid cancer	0.000319	0.000783	CcSEcCtD
Alprostadil—PTGER1—Signaling by GPCR—SST—thyroid cancer	0.000317	0.00158	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—SST—thyroid cancer	0.000317	0.00158	CbGpPWpGaD
Alprostadil—Body temperature increased—Doxorubicin—thyroid cancer	0.000306	0.000751	CcSEcCtD
Alprostadil—Abdominal pain—Doxorubicin—thyroid cancer	0.000306	0.000751	CcSEcCtD
Alprostadil—PTGIR—Signaling by GPCR—CALCA—thyroid cancer	0.000305	0.00152	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CALCA—thyroid cancer	0.000305	0.00152	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PTCH1—thyroid cancer	0.000303	0.00151	CbGpPWpGaD
Alprostadil—Asthenia—Epirubicin—thyroid cancer	0.0003	0.000737	CcSEcCtD
Alprostadil—Pruritus—Epirubicin—thyroid cancer	0.000296	0.000726	CcSEcCtD
Alprostadil—ABCC5—Disease—TPR—thyroid cancer	0.000296	0.00148	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000295	0.00147	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PRKAR1A—thyroid cancer	0.000291	0.00145	CbGpPWpGaD
Alprostadil—Diarrhoea—Epirubicin—thyroid cancer	0.000286	0.000702	CcSEcCtD
Alprostadil—ABCC5—Disease—MEN1—thyroid cancer	0.000278	0.00139	CbGpPWpGaD
Alprostadil—Asthenia—Doxorubicin—thyroid cancer	0.000278	0.000682	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—SST—thyroid cancer	0.000277	0.00138	CbGpPWpGaD
Alprostadil—Dizziness—Epirubicin—thyroid cancer	0.000276	0.000679	CcSEcCtD
Alprostadil—PTGER1—Signaling by GPCR—CDK1—thyroid cancer	0.000276	0.00138	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CDK1—thyroid cancer	0.000276	0.00138	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—IFNA2—thyroid cancer	0.000276	0.00138	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000274	0.00137	CbGpPWpGaD
Alprostadil—Pruritus—Doxorubicin—thyroid cancer	0.000274	0.000672	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—CALCA—thyroid cancer	0.000267	0.00133	CbGpPWpGaD
Alprostadil—Diarrhoea—Doxorubicin—thyroid cancer	0.000265	0.00065	CcSEcCtD
Alprostadil—Rash—Epirubicin—thyroid cancer	0.000264	0.000647	CcSEcCtD
Alprostadil—Dermatitis—Epirubicin—thyroid cancer	0.000263	0.000647	CcSEcCtD
Alprostadil—Headache—Epirubicin—thyroid cancer	0.000262	0.000643	CcSEcCtD
Alprostadil—Dizziness—Doxorubicin—thyroid cancer	0.000256	0.000628	CcSEcCtD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000251	0.00125	CbGpPWpGaD
Alprostadil—Nausea—Epirubicin—thyroid cancer	0.000248	0.00061	CcSEcCtD
Alprostadil—ABCC5—Metabolism—TPR—thyroid cancer	0.000248	0.00124	CbGpPWpGaD
Alprostadil—Rash—Doxorubicin—thyroid cancer	0.000244	0.000599	CcSEcCtD
Alprostadil—Dermatitis—Doxorubicin—thyroid cancer	0.000244	0.000598	CcSEcCtD
Alprostadil—ABCC5—Metabolism—PRKAR1A—thyroid cancer	0.000244	0.00122	CbGpPWpGaD
Alprostadil—Headache—Doxorubicin—thyroid cancer	0.000242	0.000595	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—CDK1—thyroid cancer	0.000242	0.00121	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TSHR—thyroid cancer	0.000241	0.0012	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TSHR—thyroid cancer	0.000241	0.0012	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PRKAR1A—thyroid cancer	0.000237	0.00118	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PRKAR1A—thyroid cancer	0.000237	0.00118	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000231	0.00115	CbGpPWpGaD
Alprostadil—Nausea—Doxorubicin—thyroid cancer	0.00023	0.000564	CcSEcCtD
Alprostadil—PTGER1—Signaling Pathways—MEN1—thyroid cancer	0.000226	0.00113	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MEN1—thyroid cancer	0.000226	0.00113	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CALCA—thyroid cancer	0.000221	0.0011	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PTCH1—thyroid cancer	0.000205	0.00102	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PTCH1—thyroid cancer	0.000205	0.00102	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CDK1—thyroid cancer	0.0002	0.001	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NRG1—thyroid cancer	0.000194	0.000968	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SST—thyroid cancer	0.000187	0.000935	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SST—thyroid cancer	0.000187	0.000935	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—SLC5A5—thyroid cancer	0.000185	0.000925	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CALCA—thyroid cancer	0.00018	0.0009	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CALCA—thyroid cancer	0.00018	0.0009	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TERT—thyroid cancer	0.000174	0.000869	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—NRAS—thyroid cancer	0.000173	0.000862	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—HIF1A—thyroid cancer	0.000167	0.000831	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CDK1—thyroid cancer	0.000163	0.000814	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CDK1—thyroid cancer	0.000163	0.000814	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NRG1—thyroid cancer	0.000161	0.000803	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—RXRA—thyroid cancer	0.000156	0.000777	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—KRAS—thyroid cancer	0.000149	0.000742	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—NRAS—thyroid cancer	0.000147	0.000732	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TERT—thyroid cancer	0.000144	0.000721	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HIF1A—thyroid cancer	0.000138	0.000689	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—BRAF—thyroid cancer	0.000138	0.000688	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TP53—thyroid cancer	0.000132	0.000659	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NRG1—thyroid cancer	0.000131	0.000654	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NRG1—thyroid cancer	0.000131	0.000654	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	0.000129	0.000644	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—HRAS—thyroid cancer	0.000126	0.00063	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—KRAS—thyroid cancer	0.000126	0.00063	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TERT—thyroid cancer	0.000118	0.000587	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TERT—thyroid cancer	0.000118	0.000587	CbGpPWpGaD
Alprostadil—ABCC5—Disease—BRAF—thyroid cancer	0.000114	0.000571	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HIF1A—thyroid cancer	0.000112	0.000561	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HIF1A—thyroid cancer	0.000112	0.000561	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—AKT1—thyroid cancer	0.000112	0.000557	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—HRAS—thyroid cancer	0.000107	0.000535	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—AKT1—thyroid cancer	0.000104	0.000521	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—NRAS—thyroid cancer	0.000103	0.000514	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CCND1—thyroid cancer	0.000101	0.000502	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—NRAS—thyroid cancer	9.91e-05	0.000494	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—NRAS—thyroid cancer	9.91e-05	0.000494	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PPARG—thyroid cancer	9.84e-05	0.000491	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PTEN—thyroid cancer	9.71e-05	0.000485	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—AKT1—thyroid cancer	9.48e-05	0.000473	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—BRAF—thyroid cancer	9.31e-05	0.000465	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—BRAF—thyroid cancer	9.31e-05	0.000465	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTGS2—thyroid cancer	9.24e-05	0.000461	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—KRAS—thyroid cancer	8.86e-05	0.000442	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NRAS—thyroid cancer	8.67e-05	0.000432	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—KRAS—thyroid cancer	8.53e-05	0.000426	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—KRAS—thyroid cancer	8.53e-05	0.000426	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTEN—thyroid cancer	8.06e-05	0.000402	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TP53—thyroid cancer	7.87e-05	0.000393	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PTGS2—thyroid cancer	7.74e-05	0.000386	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—HRAS—thyroid cancer	7.53e-05	0.000376	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—KRAS—thyroid cancer	7.46e-05	0.000372	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—HRAS—thyroid cancer	7.25e-05	0.000362	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—HRAS—thyroid cancer	7.25e-05	0.000362	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NRAS—thyroid cancer	7.19e-05	0.000359	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—AKT1—thyroid cancer	7.05e-05	0.000352	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—AKT1—thyroid cancer	7.05e-05	0.000352	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCND1—thyroid cancer	6.8e-05	0.000339	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCND1—thyroid cancer	6.8e-05	0.000339	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PTEN—thyroid cancer	6.75e-05	0.000337	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—AKT1—thyroid cancer	6.65e-05	0.000332	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TP53—thyroid cancer	6.63e-05	0.000331	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PTEN—thyroid cancer	6.56e-05	0.000327	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PTEN—thyroid cancer	6.56e-05	0.000327	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AKT1—thyroid cancer	6.4e-05	0.000319	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AKT1—thyroid cancer	6.4e-05	0.000319	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—HRAS—thyroid cancer	6.34e-05	0.000316	CbGpPWpGaD
Alprostadil—ABCC5—Disease—KRAS—thyroid cancer	6.19e-05	0.000309	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NRAS—thyroid cancer	5.85e-05	0.000292	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NRAS—thyroid cancer	5.85e-05	0.000292	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AKT1—thyroid cancer	5.6e-05	0.000279	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HRAS—thyroid cancer	5.26e-05	0.000262	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KRAS—thyroid cancer	5.04e-05	0.000251	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KRAS—thyroid cancer	5.04e-05	0.000251	CbGpPWpGaD
Alprostadil—ABCC5—Disease—AKT1—thyroid cancer	4.64e-05	0.000232	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TP53—thyroid cancer	4.48e-05	0.000223	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TP53—thyroid cancer	4.48e-05	0.000223	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HRAS—thyroid cancer	4.28e-05	0.000214	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HRAS—thyroid cancer	4.28e-05	0.000214	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—AKT1—thyroid cancer	3.89e-05	0.000194	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AKT1—thyroid cancer	3.78e-05	0.000189	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AKT1—thyroid cancer	3.78e-05	0.000189	CbGpPWpGaD
